Dr. McCullough arrives in New York demanding the National Cancer Institute fulfill its obligation to test ivermectin and mebendazole against cancer
The use of ivermectin-mebendazole as an adjunct to tradition cancer care is one of the biggest stories coming out of the pandemic.
The crisis was destined to have important one or more “spinoff” concepts that make a big impact in medicine. It has been rewarding to see this make the primetime news as Dr McCullough was on set in New York City with Newsmax.
In a recent segment onAmerican Agenda, hosts Katrina Szish and Bob Brooks interviewedDr. Peter McCullough, Chief Scientific Officer ofThe Wellness Company, regarding afirst-of-its-kind human observational report on the off-label use of two generic, repurposed drugs:ivermectinandmebendazole, as an adjunct therapy for cancer patients.
Theobservational report, currently under peer review, examined patients who chose to integrate these anti-infective medications into their existing cancer treatment regimens to leverage potential off-target anti-cancer properties.
Dr. McCullough expressed frustration that repurposed, off-patent medications do not receive the same research investment as proprietary therapies. He argued that theNational Cancer Institutehas an obligation to explore all treatment avenues, noting that in other medical fields, such as cardiology, the vast majority of drugs utilized are generics.
Joint Decision Making:Until comprehensive trials are completed, the approach remains one of shared decision-making between patients and their physicians.
Peter A. McCullough, MD, MPH, Chief Scientific Officer, The Wellness Company
Global Research is a reader-funded media. We do not accept any funding from corporations or governments. Help us stay afloat. Click the image below to make a one-time or recurring donation.
Comment on Global Research Articles on our Facebook page
Source: Global Research
